AstraZeneca China President currently under investigation

The two companies have decided to terminate the partnership agreement, covering the rights for Orexo to commercialize the digital mental health program for depression, Deprexis, in the US.

Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for Xbrane´s Nivolumab Biosimilar candidate (referencing Opdivo).

Kancera has announces the decision to focus its business on developing the company’s fractalkine blocking candidate drugs KAND567 and KAND145 to treat cardiovascular diseases, initially with focus on treatment of ST-elevation myocardial infarction (STEMI).

The company has announced a capital investment in the United States focused on expanding its research and manufacturing footprint by the end of 2026.

Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.

Takara Bio Europe has announced the expansion of its Gothenburg facility with the addition of a custom manufacturing lab, which came into operation on October 1st.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors.